Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck
Nivolumab, a programmed death-1 (PD-1) inhibitor, has shown promising results against squamous cell carcinoma of the head and neck (SCCHN) in cases of recurrence or in a metastatic setting after platinum-based therapy. However, treatment alternatives for patients with nivolumab-refractory are limited, and a constant opinion is not provided.Recently, accumulating studies have demonstrated that chemotherapy after immune checkpoint inhibitor treatment may induce better objective responses in patients with advanced non-small cell lung cancer.
Source: Auris, Nasus, Larynx - Category: ENT & OMF Authors: Shinsuke Suzuki, Satoshi Toyoma, Hiroki Tomizawa, Toshiki Yamada, Nobuko Iikawa, Kazuhiro Shiina, Hidekazu Saito, Koh Koizumi, Yohei Kawasaki, Takechiyo Yamada Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | ENT & OMF | Head and Neck Cancer | Laryngeal Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Skin Cancer | Squamous Cell Carcinoma | Study